Q4 2024 Twist Bioscience Corp Earnings Call Transcript
Key Points
- Twist Bioscience Corp (TWST) reported a record quarter in revenue and margin growth, with a 27% year-over-year increase in revenue to $84.7 million.
- The company achieved a gross margin of 45.1% for the quarter, exceeding guidance and demonstrating significant improvement from the previous year.
- Twist Bioscience Corp (TWST) has successfully expanded its customer base to over 3,500 customers across multiple industries, indicating strong market penetration.
- The company's Express product portfolio and NGS tools portfolio have shown continued growth, contributing positively to revenue and market share.
- Twist Bioscience Corp (TWST) is on track to reach adjusted EBITDA breakeven, with a focus on becoming cash flow positive and driving profitable growth.
- Despite revenue growth, Twist Bioscience Corp (TWST) reported an adjusted EBITDA loss of approximately $17 million for the fourth quarter.
- Operating expenses, excluding cost of revenues, remained high at $74.3 million for the quarter, highlighting challenges in cost management.
- The Biopharma segment, while showing some growth, remains a small portion of overall revenue and faces challenges in commercial execution.
- The company faces potential headwinds from competitors manufacturing outside the US, which could impact market dynamics.
- Twist Bioscience Corp (TWST) has not assumed a ramp in MRD (minimal residual disease) in its 2025 guidance, indicating uncertainty in this growth area.
Welcome to Twist Bioscience's 2024 fourth quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to turn the conference over to Angela Bitting, SVP of Corporate Affairs.
Thank you, operator. Good morning, everyone. I would like to thank you for joining us for Twist Bioscience's conference call to review our fiscal 2024 fourth quarter financial results and business progress. We issued our financial results' press release before the market, and it is available at our website at www.twistbioscience.com.
With me on the call today are Dr. Emily Leproust, CEO and Co-Founder of Twist; Adam Laponis, CFO of Twist; and Dr. Patrick Finn, President and COO of Twist.
Today, we will discuss our business progress, financial and operational performance as well as growth opportunities. We will then open the call for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
